vimarsana.com
Home
Live Updates
TREMFYA® (guselkumab) QUASAR Maintenance Study in UC me
TREMFYA® (guselkumab) QUASAR Maintenance Study in UC me
TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major secondary endpoints, including highly statistically significant rates of endoscopic remission
/PRNewswire/ -- Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001)...
Related Keywords
Washington ,
United States ,
Craig Stoltz ,
Exchange Commission ,
Johnson ,
Janssen Biotech Inc ,
None Of Janssen Research Development ,
Janssen Research Development ,
Inflammatory Bowel Disease Questionnaire ,
Innovative Medicine ,
Janssen Research ,
Janssen Biotech ,
Private Securities Litigation Reform Act ,
Annual Report ,
Note Regarding Forward Looking ,
Quarterly Reports ,